{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:20:12Z","timestamp":1780068012603,"version":"3.54.0"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1248\/bpb.b21-00212","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:08:35Z","timestamp":1630447715000},"page":"1286-1293","source":"Crossref","is-referenced-by-count":12,"title":["Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone"],"prefix":"10.1248","volume":"44","author":[{"given":"Miho","family":"Takemura","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Research and Education, Osaka University Graduate School of Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Niki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Research and Education, Osaka University Graduate School of Pharmaceutical Sciences"},{"name":"Department of Pharmacy, Ashiya Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ashiya Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Ashiya Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Omae","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Ashiya Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Pharmainformatics and Pharmacometrics, Osaka University Graduate School of Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Research and Education, Osaka University Graduate School of Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Japanese Society of Pain Clinicians. <i>Guideline for the pharmacologic management of neuropathic pain<\/i>. Shinko Trading Press, Tokyo (2016)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain\u2014an overview of Cochrane reviews. <i>Cochrane Database Syst. Rev.<\/i>, <b>7<\/b>, CD012592 (2017).","DOI":"10.1002\/14651858.CD012592"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. <i>Drug Des. Dev. Ther.<\/i>, <b>11<\/b>, 2409\u20132419 (2017).","DOI":"10.2147\/DDDT.S141007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fallon MT. Neuropathic pain in cancer. <i>Br. J. Anaesth.<\/i>, <b>111<\/b>, 105\u2013111 (2013).","DOI":"10.1093\/bja\/aet208"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Haumann J, Geurts JW, van Kuijk SM, Kremer B, Joosten EA, van den Beuken-van Everdingen MH. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. <i>Eur. J. Cancer<\/i>, <b>65<\/b>, 121\u2013129 (2016).","DOI":"10.1016\/j.ejca.2016.06.025"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Carmona-Bayonas A, Jim\u00e9nez Fonseca P, Virizuela Echaburu J. Tapentadol for cancer pain management: a narrative review. <i>Pain Pract.<\/i>, <b>17<\/b>, 1075\u20131088 (2017).","DOI":"10.1111\/papr.12556"},{"key":"7","unstructured":"7) Swarm RA, Paice JA, Anghelescu DL, <i>et al.<\/i> Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. <i>J. Natl. Compr. Canc. Netw.<\/i>, <b>17<\/b>, 977\u20131007 (2019)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Satow A, Nakatani K, Taniguchi S. Analysis of perceptual characteristics of pain describing in words caused by occupational cervicobrachial disorder and similar disease. <i>Jpn. Psychol. Res.<\/i>, <b>30<\/b>, 132\u2013143 (1988).","DOI":"10.4992\/psycholres1954.30.132"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. <i>Pain<\/i>, <b>113<\/b>, 37\u201344 (2005).","DOI":"10.1016\/j.pain.2004.09.014"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Smith HS. Opioids and neuropathic pain. <i>Pain Physician<\/i>, <b>15<\/b> (3 Suppl.), ES93\u2013ES110 (2012).","DOI":"10.36076\/ppj.2012\/15\/ES93"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ma W, Eisenach JC. Chronic constriction injury of sciatic nerve induces the up-regulation of descending inhibitory noradrenergic innervation to the lumbar dorsal horn of mice. <i>Brain Res.<\/i>, <b>970<\/b>, 110\u2013118 (2003).","DOI":"10.1016\/S0006-8993(03)02293-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hayashida KI, Clayton BA, Johnson JE, Eisenach JC. Brain derived nerve growth factor induces spinal noradrenergic fiber sprouting and enhances clonidine analgesia following nerve injury in rats. <i>Pain<\/i>, <b>136<\/b>, 348\u2013355 (2008).","DOI":"10.1016\/j.pain.2007.07.014"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chen SR, Chen H, Yuan WX, Pan HL. Increased presynaptic and postsynaptic \u03b1<sub>2<\/sub>-adrenoceptor activity in the spinal dorsal horn in painful diabetic neuropathy. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>337<\/b>, 285\u2013292 (2011).","DOI":"10.1124\/jpet.110.176586"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic \u03b1(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. <i>Pain<\/i>, <b>152<\/b>, 131\u2013139 (2011).","DOI":"10.1016\/j.pain.2010.10.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. <i>Cochrane Database Syst. Rev.<\/i>, <b>7<\/b>, CD010692 (2016).","DOI":"10.1002\/14651858.CD010692.pub3"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Derry S, Stannard C, Cole P, Wiffen PJ, Knaggs R, Aldington D, Moore RA. Fentanyl for neuropathic pain in adults. <i>Cochrane Database Syst. Rev.<\/i>, <b>10<\/b>, CD011605 (2016).","DOI":"10.1002\/14651858.CD011605.pub2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Stannard C, Gaskell H, Derry S, Aldington D, Cole P, Cooper TE, Knaggs R, Wiffen PJ, Moore RA. Hydromorphone for neuropathic pain in adults. <i>Cochrane Database Syst. Rev.<\/i>, <b>5<\/b>, CD011604 (2016).","DOI":"10.1002\/14651858.CD011604.pub2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) S\u00e1nchez Del \u00c1guila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. <i>Clin. Ther.<\/i>, <b>37<\/b>, 94\u2013113 (2015).","DOI":"10.1016\/j.clinthera.2014.07.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Pergolizzi J, B\u00f6ger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). <i>Pain Pract.<\/i>, <b>8<\/b>, 287\u2013313 (2008).","DOI":"10.1111\/j.1533-2500.2008.00204.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Zhang L, Yan X, Nobe S, Zannikos P, Etropolski M, Nandy P. Quantifying the exposure of tapentadol extended release in Japanese patients with cancer pain and bridging tapentadol pharmacokinetics across populations using a modeling approach. <i>Clin. Drug Investig.<\/i>, <b>37<\/b>, 273\u2013283 (2017).","DOI":"10.1007\/s40261-016-0482-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. <i>Clin. Pharmacol. Ther.<\/i>, <b>76<\/b>, 250\u2013269 (2004).","DOI":"10.1016\/j.clpt.2004.05.003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Turpeinen M, Zanger UM. Cytochrome P450 2B6: function, genetics, and clinical relevance. <i>Drug Metabol. Drug Interact.<\/i>, <b>27<\/b>, 185\u2013197 (2012).","DOI":"10.1515\/dmdi-2012-0027"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>58<\/b>, 417\u2013421 (2002).","DOI":"10.1007\/s00228-002-0499-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. <i>Pain Physician<\/i>, <b>17<\/b>, 329\u2013343 (2014).","DOI":"10.36076\/ppj.2014\/17\/329"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. <i>Drug Healthc. Patient Saf.<\/i>, <b>5<\/b>, 151\u2013159 (2013).","DOI":"10.2147\/DHPS.S28829"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00212\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:37:12Z","timestamp":1715143032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00212\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00212","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"b21-00212"}}